Search
Filter Results
Displaying 231–240 of 835 for “retinal diseases”
-
Jun 17, 2019
The Retina is a Proving Ground for a Broad Range of Neurological Therapies
Retinal research paves the way for new treatments for the entire neurological system.
-
Apr 29, 2021
Foundation Fighting Blindness and Usher 1F Collaborative to Launch Natural History Study
The project will help identify outcome measures for future clinical trials of potential USH1F therapies.
-
Apr 27, 2021
Foundation Fighting Blindness Appoints Claire M. Gelfman, Ph.D. as Chief Scientific Officer
Dr. Gelfman brings over twenty years of successful ophthalmic research and development experience to the Foundation executive team.
-
Jan 26, 2021
In honor of Rare Disease Day, this February 28th virtual event will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
-
A diagnosis of an inherited retinal disease (IRD) can be challenging for both patients and their doctors. But the Foundation can help eye care professionals provide resources and information to enable patients to better understand and manage their conditions, and potentially qualify for clinical trials of emerging therapies.
-
Apr 16, 2019
First Patient Receives AON Therapy for LCA10 in ProQR’s Phase 2/3 Clinical Trial
The treatment, formerly known as QR-110, is designed for people with the retinal disease Leber congenital amaurosis 10
-
Apr 25, 2018
ARVO 2018: World's Largest Show and Tell for Innovations in Eye Research
More than 11,000 eye researchers from around the world — including five intrepid members from FFB’s science team — will gather to participate in what is essentially a massive “show and tell” of the latest scientific advancements.
-
Feb 14, 2018
FFB-CRI Investing $7.5 Million in Emerging Therapy for USH2A
The Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) has entered into a partnership with ProQR to develop a retinal therapy for people with Usher syndrome type 2A (USH2A) caused by mutations in exon 13 of the USH2A gene.
-
Dec 20, 2017
History Is Made: FDA Approves Spark's Vision-Restoring Gene Therapy
Known as LUXTURNA™ (voretigene neparvovec), the gene therapy restored vision in a clinical trial for people between the ages of 4 and 44 with Leber congenital amaurosis (LCA) caused by mutations in the gene RPE65.
-
X-linked retinoschisis (XLRS) is an inherited retinal disease causing vision loss due to splitting of the layers of the retina.